| Mifeprex (mifepristone) / Danco Laboratories |
2018-002367-26: Parallel group, blinded, multi-centre study of mifepristone in patients with endometriosis |
|
|
| Ongoing | 3 | 490 | Europe | Mifepristone 2.5 mg tablets, Mifepristone 5 mg tablets, Mifepristone 2.5 mg tablets, Mifepristone 5 mg tablets, Tablet | Litaphar Laboratorios, Litaphar Laboratorios | endometriosis in reproductive-age, endometriosis in reproductive-age, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | | | | |
2020-004302-63: A multi-centre, open-label, single-arm study assessing the safety and efficacy of 5 mg of mifepristone for the treatment of endometriosis in reproductive-age women during two treatment cycles of 24 weeks each |
|
|
| Ongoing | 3 | 300 | Europe | Mifepristone 5 mg, Mifepristone 5 mg, Tablet | Litaphar Laboratorios S.L., Litaphar Laboratorios S.L. | endometriosis in reproductive-age, endometriosis in reproductive-age, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | | | | |
2019-002032-84: Evaluating the effect of a drug that at full-term preganacy, softens the neck of the womb ready for delivery Hodnocení účinku přípravku, který v období dosažení termínu porodu změkčuje hrdlo dělohy připravené na porod |
|
|
| Not yet recruiting | 2 | 150 | RoW | Mifepristone 150, Mifepristone 75, Tablet | Disphar International B.V, Disphar International B.V. | Full-term pregnancy women at week 40 + 5 of gestation with intact membranes, the first delivery, singleton physiological pregnancy těhotné ženy po dosažení termínu porodu ve stadiu týden 40 + 5 s intaktními membránami, prvorodičky, jednočetné fyziologické těhotenství, pregnant women at week 40 + 5 days of pregnancy giving birth for the first time, singleton (one fetus) pregnancy without medical complications těhotné ženy ve stadiu těhotenství 40 týdnů + 5 dní, první porod, jednočetné těhotenství bez zdravotních komplikací, Body processes [G] - Reproductive physiologi cal processes [G08] | | | | |
RESET-m, NCT05217758: edication Glucocorticoid Receptor (GR) Blockade as Disease Modifying Treatment for Depression With Childhood Trauma |
|
|
| Recruiting | 2 | 158 | Europe | Mifepristone, Placebo | VU University Medical Center, Netherlands Brain Foundation, Corcept Therapeutics | Major Depressive Disorder, Childhood Trauma | 12/23 | 06/24 | | |
TBCRC 058, NCT06099769: A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer |
|
|
| Recruiting | 2 | 201 | US | Enzalutamide, Mifepristone, TPC | Memorial Sloan Kettering Cancer Center, Astellas Pharma US, Inc., Breast Cancer Research Foundation, Corcept Therapeutics | Metastatic Breast Cancer | 10/27 | 10/27 | | |
MiMAC, NCT04905251: Effectiveness and Safety of Combination Mifepristone/Misoprostol for Medical Abortion |
|
|
| Recruiting | N/A | 3000 | Canada | Mifepristone-Misoprostol | Linepharma International LTD | Medical Abortion | 06/23 | 12/23 | | |
